Best Fit Profiles
- glycation inhibition, diabetic neuropathy support, and high-sugar-load mitigation
Advanced glycation end-product (AGE) inhibition and neuroprotection
Benfotiamine
Benfotiamine is a fat-soluble thiamine (B1) analogue with superior bioavailability. It activates transketolase, which diverts glucose metabolites away from AGE-forming pathways. Clinical trials show benefit in diabetic neuropathy and promising data on AGE accumulation reduction.
Evidence Level B
Evidence and Risk Labels
Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.
See full scoring guideClinical Snapshot
- Effect Size
- Meaningful benefit in diabetic neuropathy; modest AGE reduction in controlled studies; mechanistically strong for glycation inhibition
- Safety
- Low Risk
Generally very well tolerated. Fat-soluble so better absorbed with meals. No significant drug interactions identified at studied doses.
Research Dosing
This reflects common ranges and protocols used in published studies, not personal medical advice.
- Typical Daily Dose
- 150-300 mg
- Timing
- With meals (fat-soluble, benefits from dietary fat)
- Protocol Duration in Studies
- 12-16 weeks in neuropathy trials
Bioavailability significantly higher than standard thiamine (water-soluble B1). Used as adjunct in diabetic and glycation-focused protocols.